Mahmoud H Mosli1,2, Claire E Parker3, Sigrid A Nelson4, Kenneth A Baker3, John K MacDonald5,6, G Y Zou3,7, Brian G Feagan3,5,6,7, Reena Khanna3,6, Barrett G Levesque4, Vipul Jairath3,6,7. 1. King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia. 2. Robarts Clinical Trials, Robarts Research Institute, P.O. Box 5015, 100 Perth Drive, London, ON, Canada, N6A 5K8. 3. Robarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6. 4. Robarts Clinical Trials, San Diego, CA, USA. 5. Cochrane IBD Group, Robarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada, N6A 5B6. 6. Department of Medicine, University of Western Ontario, London, ON, Canada. 7. Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
Abstract
BACKGROUND: Disease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear. OBJECTIVES: A systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis. SEARCH METHODS: We searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies. There were no language or document type restrictions. SELECTION CRITERIA: Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated a histologic index in patients with UC were considered for inclusion. Eligible patients were adults (> 18 years), diagnosed with UC using conventional clinical, radiographic, endoscopic and histologic criteria. DATA COLLECTION AND ANALYSIS: Two authors (MHM and CEP) independently reviewed the titles and abstracts of the studies identified from the literature search. A standardized form was used to assess eligibility of trials for inclusion and for data extraction.Two authors (MHM and CEP) independently extracted and recorded data, which included the number of patients enrolled, number of patients per treatment arm, patient characteristics including age and gender distribution, and the name of the histologic index. Outcomes (i.e. intra-rater reliability, inter-rater reliability, internal consistency, content validity, criterion validity, construct validity, responsiveness, and feasibility) were recorded for each trial. MAIN RESULTS: In total, 126 reports describing 30 scoring indices were identified through the screening process. Eleven of the 30 scoring indices have undergone some form of index validation. Intra-rater reliability was assessed for eight scoring indices. Inter-rater reliability was evaluated for all 11 of the scoring indices. Three of the indices underwent content validation. Two of the included scoring indices assessed criterion validity. Six of the included scoring indices explored content validity. Two of the included scoring indices were tested for responsiveness. AUTHORS' CONCLUSIONS: The Nancy Index and the Robarts Histopathology Index have undergone the most validation in that four operating properties including reliability, content validity, construct validity (hypothesis testing) and criterion validity have been tested. However, none of the currently available histologic scoring indices have been fully validated. In order to determine the optimal endpoint for histologic healing in UC, more research is required. The optimal index would need to be fully validated.
BACKGROUND: Disease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear. OBJECTIVES: A systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis. SEARCH METHODS: We searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies. There were no language or document type restrictions. SELECTION CRITERIA: Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated a histologic index in patients with UC were considered for inclusion. Eligible patients were adults (> 18 years), diagnosed with UC using conventional clinical, radiographic, endoscopic and histologic criteria. DATA COLLECTION AND ANALYSIS: Two authors (MHM and CEP) independently reviewed the titles and abstracts of the studies identified from the literature search. A standardized form was used to assess eligibility of trials for inclusion and for data extraction.Two authors (MHM and CEP) independently extracted and recorded data, which included the number of patients enrolled, number of patients per treatment arm, patient characteristics including age and gender distribution, and the name of the histologic index. Outcomes (i.e. intra-rater reliability, inter-rater reliability, internal consistency, content validity, criterion validity, construct validity, responsiveness, and feasibility) were recorded for each trial. MAIN RESULTS: In total, 126 reports describing 30 scoring indices were identified through the screening process. Eleven of the 30 scoring indices have undergone some form of index validation. Intra-rater reliability was assessed for eight scoring indices. Inter-rater reliability was evaluated for all 11 of the scoring indices. Three of the indices underwent content validation. Two of the included scoring indices assessed criterion validity. Six of the included scoring indices explored content validity. Two of the included scoring indices were tested for responsiveness. AUTHORS' CONCLUSIONS: The Nancy Index and the Robarts Histopathology Index have undergone the most validation in that four operating properties including reliability, content validity, construct validity (hypothesis testing) and criterion validity have been tested. However, none of the currently available histologic scoring indices have been fully validated. In order to determine the optimal endpoint for histologic healing in UC, more research is required. The optimal index would need to be fully validated.
Authors: Mahmoud H Mosli; Brian G Feagan; Guangyong Zou; William J Sandborn; Geert D'Haens; Reena Khanna; Lisa M Shackelton; Christopher W Walker; Sigrid Nelson; Margaret K Vandervoort; Valerie Frisbie; Mark A Samaan; Vipul Jairath; David K Driman; Karel Geboes; Mark A Valasek; Rish K Pai; Gregory Y Lauwers; Robert Riddell; Larry W Stitt; Barrett G Levesque Journal: Gut Date: 2015-10-16 Impact factor: 23.059
Authors: P Gionchetti; F Rizzello; A Venturi; M Ferretti; C Brignola; M Miglioli; M Campieri Journal: Dis Colon Rectum Date: 1998-01 Impact factor: 4.585
Authors: R Berni Canani; G Terrin; L Rapacciuolo; E Miele; M C Siani; C Puzone; L Cosenza; A Staiano; R Troncone Journal: Dig Liver Dis Date: 2008-03-20 Impact factor: 4.088
Authors: Laura Rosenberg; Kavinderjit S Nanda; Talia Zenlea; Anne Gifford; Garrett O Lawlor; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss Journal: Clin Gastroenterol Hepatol Date: 2013-04-13 Impact factor: 11.382
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn Journal: Aliment Pharmacol Ther Date: 2020-09-27 Impact factor: 8.171
Authors: David Chen; Clifton Fulmer; Ilyssa O Gordon; Sana Syed; Ryan W Stidham; Niels Vande Casteele; Yi Qin; Katherine Falloon; Benjamin L Cohen; Robert Wyllie; Florian Rieder Journal: J Crohns Colitis Date: 2022-03-14 Impact factor: 10.020
Authors: Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath Journal: Gastroenterology Date: 2021-02-19 Impact factor: 22.682
Authors: Corinna Lang-Schwarz; Abbas Agaimy; Raja Atreya; Christoph Becker; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Michael Vieth Journal: Virchows Arch Date: 2020-12-29 Impact factor: 4.064